Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of
heparin therapy that is strongly associated with venous and arterial thrombosis (HIT and …

Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or
treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or …

Argatroban is a synthetic direct thrombin inhibitor with a relative short elimination half-life of
45 minutes and elimination which is predominantly performed via hepatic metabolism …

Heparin-induced thrombocytopenia (HIT) is an immunoglobulin-mediated serious
complication of heparin therapy characterized by thrombocytopenia and high risk for venous …

BACKGROUND: Argatroban, a direct thrombin inhibitor, is used for prophylaxis or treatment
of thrombosis in heparin-induced thrombocytopenia (HIT). The recommended initial dose is …

Background: Argatroban is a direct thrombin inhibitor approved for the prophylaxis or
treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). The …

Argatroban, a highly selective direct thrombin inhibitor, is indicated for use as an
anticoagulant for the treatment and prophylaxis of thrombosis in patients with heparin …

Background: Heparin-induced thrombocytopenia (HIT) is a serious, life-threatening
complication which occurs in 1–3% of patients receiving heparin. Patients with untreated HIT …

Argatroban is a first‐line anticoagulant for patients with heparin‐induced thrombocytopenia
(HIT). Published data on practical aspects of its use in HIT are lacking. We aim to establish …

Background Argatroban is considered to be an alternative anticoagulant of choice in
patients with heparin-induced thrombocytopenia (HIT) and renal impairment. The …